(18)F-FDG PET/CT predicts survival after (90)Y transarterial radioembolization in unresectable hepatocellular carcinoma.

Details

Serval ID
serval:BIB_E1E635AA8F47
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
(18)F-FDG PET/CT predicts survival after (90)Y transarterial radioembolization in unresectable hepatocellular carcinoma.
Journal
European journal of nuclear medicine and molecular imaging
Author(s)
Jreige M., Mitsakis P., Van Der Gucht A., Pomoni A., Silva-Monteiro M., Gnesin S., Boubaker A., Nicod-Lalonde M., Duran R., Prior J.O., Denys A., Schaefer N.
ISSN
1619-7089 (Electronic)
ISSN-L
1619-7070
Publication state
Published
Issued date
07/2017
Peer-reviewed
Oui
Volume
44
Number
7
Pages
1215-1222
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
To compare the value of pretreatment functional and morphological imaging parameters for predicting survival in patients undergoing transarterial radioembolization using yttrium-90 ((90)Y-TARE) for unresectable hepatocellular carcinoma (uHCC).
We analysed data from 48 patients in our prospective database undergoing (90)Y-TARE treatment for uHCC (31 resin, 17 glass). All patients underwent (18)F-FDG PET/CT and morphological imaging (CT and MRI scans) as part of a pretherapeutic work-up. Patients did not receive any treatment between these imaging procedures and (90)Y-TARE. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) were used to assess the prognostic value of (18)F-FDG PET/CT metabolic parameters, including SUVmax, tumour-to-liver (T/L) uptake ratio and SUVmean of healthy liver, and morphological data, including number and size of lesions, portal-venous infiltration (PVI). Relevant prognostic factors for HCC including Child-Pugh class, Barcelona Clinic Liver Cancer (BCLC) stage, tumour size, PVI and serum AFP level were compared with metabolic parameters in univariate and multivariate analyses.
The median follow-up in living patients was 16.2 months (range 11.4-50.1 months). Relapse occurred in 34 patients (70.8%) at a median of 7.4 months (range 1.4-27.9 months) after (90)Y-TARE, and relapse occurred in 24 of 34 patients (70.8%) who died from their disease at a median of 8.1 months (range 2.2-35.2 months). Significant prognostic markers for PFS were the mean and median lesion SUVmax (both P = 0.01; median PFS 10.2 vs. 7.4 months), and significant prognostic markers for OS were the first quarter (Q1) cut-off values for lesion SUVmax and T/L uptake ratio (both P = 0.02; median OS 30.9 vs. 9 months). The multivariate analysis confirmed that lesion SUVmax and T/L uptake ratio were independent negative predictors of PFS (hazard ratio, HR, 2.7, 95% CI 1.2-6.1, P = 0.02, for mean SUVmax; HR 2.6, 95% CI 1.1-5.9, P = 0.02, for median SUVmax:) and OS (HR 3.2, 95% CI 1-10.9, P = 0.04 for Q1 SUVmax; HR 3.7, 95% CI 1.1-12.2, P = 0.03, for Q1 T/L uptake ratio), respectively, when testing with either the BCLC staging system or serum AFP level.
Lesion SUVmax and T/L uptake ratio as assessed by (18)F-FDG PET/CT, but not morphological imaging, were predictive markers of survival in patients undergoing (90)Y-TARE for uHCC.

Keywords
Aged, Arteries, Carcinoma, Hepatocellular/diagnostic imaging, Carcinoma, Hepatocellular/radiotherapy, Carcinoma, Hepatocellular/surgery, Disease-Free Survival, Embolization, Therapeutic, Female, Fluorodeoxyglucose F18, Humans, Liver Neoplasms/diagnostic imaging, Liver Neoplasms/radiotherapy, Liver Neoplasms/surgery, Male, Middle Aged, Positron Emission Tomography Computed Tomography, Survival Analysis, Yttrium Radioisotopes/therapeutic use, FDG PET/CT, Hepatocellular carcinoma, Imaging, Survival, TARE
Pubmed
Web of science
Create date
07/03/2017 21:30
Last modification date
04/11/2019 16:24
Usage data